Pricing Log in Create free account
Saturday 17 October 2026 Export AMGN’s income statement to Excel — free account

Amgen Inc.

AMGN Healthcare Drug Manufacturers General

Amgen Inc.’s revenue for fiscal 2025 (year ended December 2025) was $36.8 billion, up 9.95% from fiscal 2024. In the quarter to June 2026, revenue grew 9.53%, EPS grew 65.4%, free cash flow grew 82.6% and total debt rose 1.96%, each against the same quarter a year earlier. Member of the S&P 500, Nasdaq 100 and Dow Jones; dividend growth for ten consecutive years, revenue growth for five.

432.49 1.54 −0.35%
Market cap
$234.7B
P/E
26.7×
Fwd P/E
22.7×
Dividend yield
2.30%
F-score
7/9
Altman Z
1.69
Beneish M
−2.27
Dividend safety
56/100
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Amgen Inc. (AMGN) EV/EBITDA

Alert me on EV/EBITDA

As of 16 October 2026, Amgen Inc. (AMGN) trades at a EV/EBITDA of 16.8×. Over the past ten years it has ranged from 8.6× (November 2016) to 19.2× (September 2024); the current reading is higher than 94% of that period. That is above the Drug Manufacturers General industry median of 13.8× and above the Healthcare sector median of 9.2×.

EV/EBITDA, daily

Embed this chart

Annual newest first

Period EV/EBITDA Change
FY2025 14.3× (0.79%)
FY2024 14.5× (12.89%)
FY2023 16.6× 26.46%
FY2022 13.1× (5.63%)
FY2021 13.9× 12.81%
FY2020 12.3× (12.21%)
FY2019 14.0× 28.63%
FY2018 10.9× 5.84%
FY2017 10.3× 12.35%
FY2016 9.2× (21.09%)

Quarterly newest first

Period EV/EBITDA Change
Jun 2026 14.5× (2.35%)
Mar 2026 14.8× 3.40%
Dec 2025 14.3× 11.66%
Sep 2025 12.8× (5.44%)
42 more quarters

Against its own ten years

Low 8.6× High 19.2×
Ten-year median 12.9×
Current reading's percentile 94

EV/EBITDA against peers

Company EV/EBITDA
NVO Novo Nordisk A/S compare 7.0×
BMY Bristol Myers Squibb Company compare 10.2×
PFE Pfizer Inc. compare 10.8×
AZN AstraZeneca PLC compare 13.8×
NVS Novartis AG compare 14.5×
AMGN Amgen Inc. 16.8×
ABBV AbbVie Inc. compare 22.2×
MRK Merck & Co., Inc. compare 29.5×
GILD Gilead Sciences, Inc. compare 829×
Drug Manufacturers General industry median 13.8×
Healthcare sector median 9.2×
Market median 11.0×

What EV/EBITDA is

Enterprise Value over EBITDA tells an investor how the market values a whole company, with debt added and cash taken off, against its operating earnings.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ EBITDA (TTM)

The full definition of EV/EBITDA →

More on AMGN